ICON Announces Appointment of Mr. Ronan Murphy to Board of Directors
24 Outubro 2016 - 8:00AM
Business Wire
ICON plc, (NASDAQ:ICLR) global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Mr. Ronan Murphy as a non-executive director.
Mr. Murphy is the former Senior Partner of PwC, Ireland's
largest professional services firm with almost 100 partners and
employing over 2,000 people. Mr. Murphy was elected Senior Partner
in 2007 and was re-elected for a further four year term in 2011.
Following completion of the maximum two terms, Mr. Murphy retired
from the firm in June 2015. Mr. Murphy was also a member of the PwC
EMEA Leadership Board for a five year period from 2010 to 2015.
Mr. Murphy joined PwC in 1980 and was admitted to the
Partnership in 1992. As an Assurance Partner, he served clients
across many sectors. In 1995, Mr. Murphy joined the firm’s
leadership team and held a number of operational leadership roles,
prior to being appointed as Partner in Charge of the firm's
Assurance Practice in 2003, a position he held for four years prior
to his appointment as Senior Partner.
In early 2016, Mr. Murphy was appointed as a non-executive
director of Davy Stockbrokers, and he chairs their Audit Committee.
He is also a Director of Liberty Insurance's operations in Ireland
and also chairs the Audit Committee.
Mr. Murphy currently serves as a Board Member of the UCD Michael
Smurfit Business School and is a founding Board Member of the
British Irish Chamber of Commerce.
Mr. Murphy completed a Bachelor of Commerce and Masters in
Business Studies at University College Dublin before qualifying as
a chartered accountant in 1982.
"I am very pleased that Mr. Murphy has joined the board"
commented Mr. Declan McKeon, acting Chairman of the Board. "His
leadership of PwC, Ireland’s largest professional services firm,
and his extensive business experience and expertise across many
industry sectors will bring invaluable expertise to the ICON
board”.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 88 locations in 37 countries and has approximately
12,600 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024005521/en/
ICON plcContact:Investor Relations1-888-381-7923orBrendan
BrennanChief Financial Officer+ 353 –1-291-2000orSimon HolmesEVP
Investor Relations and Corporate Development+ 353 –1-291-2000
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024